Angiotech's corporate partner, Boston Scientific, submits final modules to FDA for approval of second-generation small vessel and long lesion stents

    Journal of American College of Cardiology publishes positive ATLAS
    clinical data

    VANCOUVER, Feb. 5 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:   ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
announced that its corporate partner, Boston Scientific, has submitted the
final modules for pre-market approval (PMA) for both its TAXUS(R) Liberté(R)
Atom(TM) Paclitaxel-Eluting Coronary Stent System and its TAXUS(R) Liberté
Long(TM) Paclitaxel-Eluting Coronary Stent System to the U.S. Food and Drug
Administration (FDA). If approved, the TAXUS Liberté Atom Stent will become
Boston Scientific's second 2.25 mm diameter drug-eluting stent (DES) available
in the United States. It will then likely succeed the TAXUS Express(TM) Atom
Stent, which is Boston Scientific's first approved small stent and the only
DES currently approved by the FDA to treat small vessels. The TAXUS Liberté
Long Stent is designed to be the first 38 mm drug-eluting stent available in
the U.S. and will further expand this leading DES portfolio.
    "We are pleased to have a second-generation small vessel DES and the U.S.
market's first long DES under review by the FDA," said Jim Tobin, President
and Chief Executive Officer of Boston Scientific. "The rapid adoption of our
recently approved TAXUS Express Atom Stent confirms the need for an expanded
DES size matrix to treat the wide range of vessel anatomies seen in daily
clinical practice."
    These PMA submissions include clinical data from the global, multi-center
TAXUS ATLAS Small Vessel (SV) and Long Lesion (LL) studies, designed to
compare the performance of the TAXUS Liberté Atom and TAXUS Liberté Long
Stents with Boston Scientific's first-generation TAXUS Express Stent. While
the second-generation TAXUS Liberté Stent uses identical drug dose, polymer
and release kinetics as the TAXUS Express Stent, it features thinner struts
and a uniform architecture specifically designed for drug delivery.
    One-year results from the TAXUS ATLAS SV and LL studies were published in
the December 2008 issue of the Journal of American College of Cardiology. The
studies both met their primary endpoint of non-inferior, nine-month,
in-segment diameter stenosis versus the TAXUS Express Stent control group.
They reported a significant reduction in small vessel in-stent restenosis and
major adverse coronary events (MACE) in patients treated with the TAXUS
Liberté Atom Stent, and a significantly reduced rate of myocardial infarction
(heart attack) in patients with long lesions treated with the TAXUS Liberté
Long Stent.
    "In the ATLAS study, lower target lesion revascularization (TLR) rates
contributed to a significantly lower rate of MACE, including heart attacks,
with the TAXUS Liberté Atom Stent," said Mark A. Turco, M.D., Director of the
Center for Cardiac and Vascular Research, Washington Adventist Hospital, and
Co-Principal Investigator of the ATLAS trial. "The thinner struts of the TAXUS
Liberté Atom Stent are designed to improve its deliverability and
conformability, which is important when treating small vessels. The TAXUS
Liberté Stent also features an advanced stent cell geometry that has been
designed to allow for more consistent drug distribution."
    Patients with small vessels treated with the TAXUS Liberté Atom Stent
reported significantly lower nine-month angiographic in-segment late loss
(0.16 mm vs. 0.32 mm, p=0.0146), reduced nine-month angiographic restenosis
(18.5% vs. 32.7%, p=0.0219), reduced 12-month TLR (6.1% vs. 16.9%, p=0.0039),
and reduced rates of stent thrombosis (0.4% vs. 1.5%, p=0.39). Patients with
long lesions treated with the TAXUS Liberté Long Stent reported a
significantly reduced 12-month rate of myocardial infarction (1.4% vs. 6.5%,
p= 0.0246) as well as a trend toward fewer stent thromboses (0% vs. 0.7%,
    Boston Scientific remains the overall drug-eluting stent market leader in
the United States, with a 49 percent share of the market in December. The
Company released three major DES products in the United States in 2008
including the TAXUS Express Atom Stent and the TAXUS Liberté Stent. Boston
Scientific expects to launch its third-generation drug-eluting stents,
including the TAXUS Element(TM) Paclitaxel-Eluting Coronary Stent, in Europe
later this year.
    The TAXUS Liberté Atom, TAXUS Liberté Long and TAXUS Element stents are
investigational devices and are restricted under U.S. law to investigational
use only.

    Forward Looking Statements

    Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimate," "continue," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the fourth quarter of 2008 and
beyond, our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research, development, product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, events or developments to be materially
different from any future results, events or developments expressed or implied
by such forward-looking statements. Many such risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions, both nationally and in the regions in which
we operate; market demand; technological changes that could impact our
existing products or our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or the failure
to comply with, governmental regulations; adverse results or unexpected delays
in pre-clinical and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; the requirement
for substantial funding to conduct research and development and to expand
manufacturing and commercialization activities or consummate acquisitions; and
any other factors that may affect performance. In addition, our business is
subject to certain operating risks that may cause the actual results expressed
or implied by the forward-looking statements in this press release to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from third
party challenges to our patents; commercialization limitations imposed by
patents owned or controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued availability of
capital to finance our activities; and any other factors referenced in our
other filings with the Securities and Exchange Commission ("SEC") and
applicable Canadian regulatory authorities. For a more thorough discussion of
the risks associated with our business, see the "Risk Factors" section in our
annual report for the year ended December 31, 2007 filed with the SEC on Form
40-F and our quarterly report for the three months ended September 30, 2008
filed with the SEC on Form 10-Q.
    Given these uncertainties, assumptions and risk factors, readers are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.

    (C)2009 Angiotech Pharmaceuticals, Inc.  All Rights Reserved.

    Boston Scientific Corporation acquired worldwide exclusive rights from
Angiotech to use paclitaxel to coat its coronary stent products and has
co-exclusive rights to certain peripheral vascular and non-vascular products.

    TAXUS(R) Liberté(R) Atom(TM) and Long(TM) are registered trademarks of
Boston Scientific Corporation.

    About Angiotech Pharmaceuticals

    Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ:   ANPI, TSX: ANP),
please visit our website at

For further information:

For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,

Organization Profile

Angiotech Pharmaceuticals, Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890